The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
Open accessAbstract
Objective: To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson's disease Design: Open, long term, prospective randomised trial. Setting: 93 hospitals throughout United Kingdom Subjects: 520 patients with early Parkinson's disease who were not receiving dopaminergic treatment. Interventions: Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2). Main outcome measures Assessments of serial disability, frequency and severity of adverse events, and deaths from all causes. Results: After average of 5.6 years' follow up, mortality ratio in arm 2 compared with arm 1 was 1.57 (95% confidence interval 1.09 to 2.30), and difference in survival between the two arms was significant (log rank test, P=0.015). Hazard ratio adjusted for age and sex was 1.49 (1.02 to 2.16), and after adjustment for other baseline factors it increased to 1.57 (1.07 to 2.31). Patients in arm 1 had slightly worse disability scores than those in arm 2, but differences were not significant. Functionally disabling peak dose dyskinesias and on/off fluctuations were more frequent in arm 2 than arm 1. During the trial the dose of levodopa required to produce optimum motor control steadily increased in arm 1 (median daily dose 375 mg at 1 year and 625 mg at 4 years), but median dose in arm 2 did not change (375 mg). Conclusion: Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease. Moreover, mortality was significantly higher with combination treatment, casting doubts on its chronic use in Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Self-citation"ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY
Marsden, C. D., & Parkes, J. D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91416-1 · Cited by 661
Critical analysis of the disability in Parkinson's disease.
Webster, D. D. (1968) · PubMed · Cited by 488
Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
Tatton, W. G., & Greenwood, C. E. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490300410 · Cited by 272
A METHOD FOR EVALUATING DISABILITY IN PATIENTS WITH PARKINSONʼS DISEASE
CANTER, G. J., de La TORRE, R., & MIER, M. (1961) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196108000-00010 · Cited by 220
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
Cohen, G., & Spina, M. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260518 · Cited by 211
The Impact of Treatment with Levodopa on Parkinson's Disease
(1980) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a067623 · Cited by 164
Low‐dose L‐dopa therapy in Parkinson's disease: A 6‐year follow‐up study
Poewe, W. H., Lees, A. J., & Stern, G. M. (1986) · Neurology · doi:10.1212/wnl.36.11.1528 · Cited by 163
Self-citationDoes levodopa therapy delay death in Parkinson's disease? A review of the evidence
Clarke, C. E. (1995) · Movement Disorders · doi:10.1002/mds.870100303 · Cited by 84
Ward, C. D. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.2.217 · Cited by 74
Cited by
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
A review of Parkinson's disease
Davie, C. A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn013 · Cited by 855
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Metadata
- Authors
- Lees, A. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1995-12-16
- Volume
- 311
- Issue
- 7020
- Pages
- 1602-1607
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1516230268
- Cited by
- 346
- References
- 12
- FWCI
- 23.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.